GMP Companies Report issue

For profit Phase 2 Phase 3
Founded: Fort Lauderdale FL United States (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2001
NCT00034255
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

GMP-Orphan SAS

Active Ingredients

Drugs in Phase 3 Trials (2)

penicillamine (cuprimine) (1 trial)

triethylenetetramine (trientine) (1 trial)

Drugs in Phase 2 Trials (1)

ingap peptide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Hepatolenticular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3